Amgen awaiting to acquire Regeneron for cheap

Quote

anonymous

Guest
Amgen is waiting for the Praluent appeal to be upheld as the burden for Regeneron is high to have it overturned. If timing holds, Amgen can bring in cash via President Trump to fund the acquisition of Regeneron since their market capitalization will reflect the lack of praluent future revenue. Amgen will arguably have the most value in getting Regeneron at this depressed price because they can restore Praluent to the market. Amgen will take both Dupi and sarilumab and insert them with the Inflammation business unit. They will scavenge Regeneron's pipeline for anything worthwhile and then sell off Elyea and Praluent (on their terms) to other companies. Basically, Amgen's getting to dumpster dive if this injunction holds up.

An Amgen acquisitions means this:

1. Elyea - Anyone associated with this is moving to whatever company Amgen sells to. Top choice is Bayer.

2. Praluent - You will likely be fired and the marketing will resume once Amgen allows it onto market with the new company. They will likely keep the asset close to vest until they believe the Alnylam RNAi PCSK9 is close to market and their monopoly will be over. For most of you, it means look for another job in the meantime.

3. Dupi and Sari - you are going to be integrated into Amgen. Amgen will decide who they want to keep and it won't be many. Ask Onyx Pharmaceuticals folks how the transition went. Lots of horror stories.

4. Pipeline assets - you will either be kept if Amgen has strong interest in the program or licensed out to another company.

5. Tarrytown site will be shutdown once transitions are completed.

Sorry for the bad news, best to hope the injunction does not hold. Amgen culture will not be inviting to anyone who wants to work there. No warm welcome from Amgen.
 






This is the most autistic thing I've read in a long time. Regeneron just invested nearly a BILLION dollars in real estate in the Westchester area and you're trying to say that they are going to fold their cards and cash out? Absurd. Thank you here's you participation ribbon, now go along your way.
 












anonymous said:
This is the most autistic thing I've read in a long time. Regeneron just invested nearly a BILLION dollars in real estate in the Westchester area and you're trying to say that they are going to fold their cards and cash out? Absurd. Thank you here's you participation ribbon, now go along your way.
Click to expand...


It's not Regeneron's decision. If the stock tanks because the injunction is permanent, if Amgen buys the company. They will shutdown and sell off the real estate. Ask Onyx Pharmaceuticals what happened to their SSF buildings.
 












Don't get too worked up. A lot of people from Update NY grew up in a very secluded environment with an abundance of ignorance. For example, this entire thread is about a potential Amgen acquisition and someone chimes in with, "Westchester will not give up the $1 billion purchase". Obviously, reading comprehension is an issue (among other issues such as diversity, accepting new ideas, let alone the most basics such as grammar).

Oh, by the way, that's partly why REGN is in a heap of trouble.
 






anonymous said:
Don't get too worked up. A lot of people from Update NY grew up in a very secluded environment with an abundance of ignorance. For example, this entire thread is about a potential Amgen acquisition and someone chimes in with, "Westchester will not give up the $1 billion purchase". Obviously, reading comprehension is an issue (among other issues such as diversity, accepting new ideas, let alone the most basics such as grammar).

Oh, by the way, that's partly why REGN is in a heap of trouble.
Click to expand...

Those darn Trump supporters!

Amgen buys you, you are there bitch. They can shutdown Westchester. This isn't exporting jobs to Mexico so Trump can't do anything.
 












This is a great theory if not for one GLARING fact:

SANOFI SHARES THE RIGHTS OF ALL OF REGENERONS MARKETED PRODUCTS UNTIL 2020. With an option to re-up to an even LATER date (2029) this very next year of 2018.

The contract is simple and easy to find with a simple google search. Until 2020, Regeneron is untouchable. Unless, of course, Amgen is willing to pay the ASTRONOMICAL fee ($20B) to break the contract between the two entities... but I find it highly unlikely they would agree to such terms.

So, until then, troll.... do your homework before you try and shake things up over here on CP.
 






anonymous said:
This is a great theory if not for one GLARING fact:

SANOFI SHARES THE RIGHTS OF ALL OF REGENERONS MARKETED PRODUCTS UNTIL 2020. With an option to re-up to an even LATER date (2029) this very next year of 2018.

The contract is simple and easy to find with a simple google search. Until 2020, Regeneron is untouchable. Unless, of course, Amgen is willing to pay the ASTRONOMICAL fee ($20B) to break the contract between the two entities... but I find it highly unlikely they would agree to such terms.

So, until then, troll.... do your homework before you try and shake things up over here on CP.
Click to expand...


Do your fucking homework junior. Abbvie bought 1 product pharmacyclics for $21B and half the drugs revenue goes to JnJ. Similar structure doofus. Even if sanofi buys Regeneron they get value for praluent unless they say "pretty please" to Amgen! Or lick Amgen's anus like your wife does to me.
 






Regeneron has no money. They've been spending Sanofi's money. Sanofi ownes 20% of Regeneron's stock. Once that contract ended and Sanofi cuts ties with Regeneron, they'll have no money to operate with.
 






anonymous said:
Regeneron has no money. They've been spending Sanofi's money. Sanofi ownes 20% of Regeneron's stock. Once that contract ended and Sanofi cuts ties with Regeneron, they'll have no money to operate with.
Click to expand...

That is correct. Sanofi owns approximately 20.4% of REGN with the option to purchase 30% more in 2017 via the Immuno-oncology agreement. Sari is delayed. Dupi may not even be approved.

REGN needs to establish a great business case to beat out companies like Actellion, ImmuNext, etc. for further Sanofi investment.

One saving grace for REGN is Opthotech's failure - Eylea is safe - For Now.

With the Praluent cluster fuck REGN is worth about $325/share. If after appeal, the injunction stands, then REGN goes down to $250/share. If Sari/Dupi incur additional problems, then HELLO ACQUISITION.

Keep in mind all this information will unfold this year.
 


















Amgen announced that the US District Court of Delaware denied Sanofi's and Regeneron's motion to stay (suspend) the injunction pending the appeal of the ongoing PCSK9 litigation in the Court of Appeals for the Federal Circuit (CAFC). In this ruling, the District Court did extend the timing of the injunction from 30 to 45 days, allowing Sanofi and Regeneron to seek review of the Court's injunction and stay denial at the CAFC.

Additionally, Amgen announced during the 35th annual J.P. Morgan Healthcare Conference that the company will present Repatha cardiovascular outcomes (CVOT) data at the American College of Cardiology Conference (ACC) taking place in Washington D.C. on 17-19 March 2017.

Denying the stay could accelerate both the appeal process and potential Praluent removal from the US. In light of yesterday's block of the injunction stay and after our further consultation with expert legal counsel, we now believe that the appeals process is likely to be substantially accelerated, with a potential final decision from the CAFC as early as April 2017. Since we continue our belief that there is a greater than 75% likelihood that the CAFC will uphold the original decision on the injunction, we now believe it is possible that Praluent could be removed from the US market within a few months.
 






anonymous said:
Amgen announced that the US District Court of Delaware denied Sanofi's and Regeneron's motion to stay (suspend) the injunction pending the appeal of the ongoing PCSK9 litigation in the Court of Appeals for the Federal Circuit (CAFC). In this ruling, the District Court did extend the timing of the injunction from 30 to 45 days, allowing Sanofi and Regeneron to seek review of the Court's injunction and stay denial at the CAFC.

Additionally, Amgen announced during the 35th annual J.P. Morgan Healthcare Conference that the company will present Repatha cardiovascular outcomes (CVOT) data at the American College of Cardiology Conference (ACC) taking place in Washington D.C. on 17-19 March 2017.

Denying the stay could accelerate both the appeal process and potential Praluent removal from the US. In light of yesterday's block of the injunction stay and after our further consultation with expert legal counsel, we now believe that the appeals process is likely to be substantially accelerated, with a potential final decision from the CAFC as early as April 2017. Since we continue our belief that there is a greater than 75% likelihood that the CAFC will uphold the original decision on the injunction, we now believe it is possible that Praluent could be removed from the US market within a few months.
Click to expand...

Regeneron proceeded with a known calculated risk and lost. This will be a multi-billion dollar lesson to management.
 






  • Praluent won't likely get a stay during the appeal so product likely pulled in Q1
  • Even after 18 month appeal, Praluent injunction likely to be upheld
  • Amgen never settles IP cases and only 20% of cases like this ever go to royalties.

http://www.investors.com/news/techn...eneron-sanofi-in-amgen-patent-battle-leerink/

Biotech Amgen (AMGN) will likely triumph in a patent battle with Regeneron Pharmaceuticals (REGN) and Sanofi (SNY), requiring the duo to pull LDL-buster Praluent from the shelves — an unprecedented first, Leerink analyst Geoffrey Porges said Friday.

Regeneron and Sanofi have asked a federal circuit judge to grant a stay of the injunction beyond 45 days. That would allow them to market Praluent during the appeal, which typically runs up 16 months, Porges wrote in a research report Friday.

But the odds don't look good. Specialists believe "regardless of the ultimate merits of Regeneron and Sanofi's case, they will face an unprecedented (and probably first) branded pharmaceutical product withdrawal in the middle of this quarter," he wrote.

The most important catalyst will be whether the Federal Circuit extends the stay, Porges says. Of 158 permanent injunctions (PIs) granted in federal or district court since a 2006 case involving Ebay, only 37 parties (23%) were granted a stay.

In Regeneron and Sanofi's case, though, it would be the first time a branded drug would be pulled from shelves as a result of patent litigation. They have made the argument that public interest would not be served by pulling Praluent, which offers a lower dosage than Amgen's Repatha.

Examining medical-device cases, the district court has stayed a PI in five cases. But at the federal level, the PI was affirmed and not extended, resulting in the removal of those products from the market. Those precedents appear to be "stacked" against Regeneron and Sanofi, Porges said.

To Regeneron and Sanofi's public interest argument, Porges noted that public interest is actually better served in siding with the patent holder, thus encouraging the risky investment required in bringing an innovative product to market.

Porges also looks at several outcomes. It's possible that the case could be remanded to the district court. The federal circuit could also require Amgen, Regeneron and Sanofi to seek settlement assistance via the Circuit Mediation Office. But that process only happens in 10%-20% of cases.

Amgen, the No. 1 biotech firm by market cap, is unlikely to settle, he wrote. The company "notoriously takes the stance to never settle IP disputes and vigorously defends the company's IP, as evidenced by the blockage of market entry for Roche's Epogen competitor Mircera until the infringed patent expired."
 












Top Bottom
Back
Quote